Exercise performance and hematological responses have been shown to be variable, both in response to exercise at altitude and on return to sea level after altitude training (Chapman et al., 1998; Chapman, 2013) . Practitioners and coaches should, therefore, consider individualizing an athlete's post-altitude training strategy to optimize the benefits of the camp. Elite coach, Dick (1992) , discussed training at altitude in practice and suggested that on return from altitude, time was needed to reach a stage where performance shows a clear sign of benefit. Although these assumptions were based on the training status of the athlete, there is hematological evidence to suggest that there is a "re-acclimatization" that occurs when returning to sea level from altitude. Garvican et al. (2012) observed a 1.5% decrease in total heamoglobin mass (tHbmass) within 3 days of decent from a 3-week natural altitude training camp, which persisted when measured 10 days after decent. Pottgiesser et al. (2012) also found that after a 26 night simulated altitude training camp, there was a 3.0% reduction in tHbmass within 9 days at sea level. Likewise, both Brugniaux et al. (2006) and Heinicke et al. (2005) found an initial increase in tHbmass as a result of simulated and natural 'live high-train low', respectively, but tHbmass returned to baseline levels within 15-16 days at sea level. Prommer et al. (2009) found that when natural altitude dwellers reside at sea level for sustained durations, a reduction in tHbmass occurs. The study found that tHbmass remained stable within the first 2 weeks at sea level followed by a reduction of~2% per week before leveling off around 5-6 weeks postaltitude. The reduction in tHbmass was attributed to transiently suppressed erythropoietin (EPO) as a result of returning to a normoxic environment . The removal of the altitude stimulus appears to result in a re-acclimatization to sea level (Garvican et al., 2012) . Chapman et al. (2014) stated that if an athlete completes a 4-week altitude training camp, followed by a short time (~7 to 14 days) at sea level to compete, returning to altitude even for a short time may mitigate or delay these effects by re-establishing EPO levels again.
Brief periods of severe hypoxia have been suggested as a potential method to prevent the sudden decrease in EPO (Pottgiesser et al., 2012 ). This in turn would preserve the hematological acclimatization response for a longer time, thereby expanding the window for endurance training and optimal competition racing (Chapman et al., 2014) . Figure 1 illustrates the previous investigations that have demonstrated an increase in EPO as a result of hypoxic exposures lasting 5 min to 5.5 h (Eckardt et al., 1989; Knaupp et al., 1992; Rodr ıguez et al., 2000; Ge et al., 2002; Niess et al., 2004; Friedmann et al., 2005; MacKenzie et al., 2008; Wahl et al., 2013) . The chart bubble size represents the magnitude of EPO production in response to exposure time and simulated altitude (i.e., the larger the bubble, the greater the production of EPO). Collectively, these findings suggest that a minimum time period of 2 h at an altitude of >2500 m elicits a significant increase in EPO. Although it should be noted that these studies have used differing methods (hypobaric vs normobaric), physical status (rest vs exercise), and varied timing of blood sampling, that may not be accessible or possible in different scenarios. Stray-Gundersen et al. (2001) believed that when athletes attend altitude training camps, it is possible that the presence of injury or infection, and therefore proinflammatory cytokines [such as interleukin-6 (IL-6) and tumor necrosis factor-a (TNFa)], could impair the erythropoietic response to altitude (Faquin et al., 1992; Jelkmann et al., 1992) . Hypoxia is a stressor that alters homeostasis [subsequent to a reduction in arterial oxygen (O 2 ) saturation] and may result in an inflammatory response (Mazzeo et al., 2013) . Previous research has found that after three nights at elevations higher than 3400 m, the levels of IL-6 and C-reactive protein were increased in individuals with acute mountain sickness (AMS) (Hartmann et al., 2000) , and similarly, after 12 nights at 4300 m, IL-6 was elevated (Mazzeo et al., 2013) . Conversely, Schobersberger et al. (2004) found that after a 3-week sojourn (living and hiking) at moderate altitude (1700-2500 m), there were no differences in IL-6 or TNFa in clinical trials of individuals with metabolic syndrome. As a result, if additional hypoxic exposures are to be considered post-altitude training, then the role of proinflammatory cytokines and EPO production should be investigated.
Altitude training is a common practice undertaken by endurance athletes in pursuit of an enhancement of subsequent sea-level performance (Fudge et al., 2012) ; however, identifying the best time to return to sea level prior to a major competition to optimize the hematological gains remains a question (Chapman et al., 2014) . A minimum hypoxic exposure of 2 h is required to elicit an increase in EPO; however, less is understood about the effect of a 2 h exposure of normobaric hypoxia on EPO and the time course of this response. Furthermore, the response of inflammatory cytokines to differing levels of hypoxia in healthy individuals is unclear. The aim of this study was to establish the dose-response relationship of EPO, alongside markers of inflammation IL-6 and TNFa, during and following 2 h exposures of normobaric hypoxia with the intention of mitigating neocytolysis. Then, we hypothesized that [EPO] would increase following 2 h normobaric hypoxic exposure, and the increase would be in accordance with the severity of hypoxia. Basal levels of proinflammatory cytokines would inhibit the production of [EPO] in participants.
Method Participants
Eight physically active, Caucasian men participated in the study (Table 1) . Participants were well trained, completing 8 AE 3 h training per week. Institutional ethical approval was issued in accordance with the Helsinki declaration 1975 Helsinki declaration (revised 2013 , and participants provided written informed consent. Participants were non-smokers and had not been exposed to altitudes above 2000 m in the preceding 2 months. Participants were instructed not to consume alcohol or caffeine during a period of at least 24 h immediately preceding each trial and maintained their normal training regimen during the testing period.
Experimental design
The outline of this single-blind, randomized, controlled study is presented in Fig. 2 . Participants attended the laboratory in Eastbourne, United Kingdom (10-m altitude), on an individual basis on five separate occasions: once for preliminary measurements; thrice involved resting in a hypoxic environment at three different levels of hypoxia, and once for resting in normoxia. Participants were required to attend the laboratory for eight and a half hours for each experimental trial. They were instructed to eat the same breakfast before each visit, were supplied with a standardized isocaloric lunch, and drank water ad libitum throughout the testing procedure. The order of the trials was randomized, determined by a Latin squares design. Each trial was separated by a 7-day wash-out period (MacKenzie et al., 2008) . All trials commenced at the same time for each individual participant between 07:30 and 09:30 hours, to control for diurnal variations in EPO (Klausen et al., 1993 (Klausen et al., , 1996 .
Preliminary measures
Anthropometric data were collected with body mass measured using digital scales (GFK 150, Adam Equipment Inc., Danbury, CT, USA) and body fat assessed from four sites (biceps, triceps, subscapular, and supra-iliac) as described by Durnin and Womersley (1974) using skinfold calipers (Harpenden, Burgess Hill, UK). For the assessment of aerobic capacity, participants then performed a standardized stepwise incremental test on a cycle ergometer. Cycling started at 80 W, increasing by 24 W each minute, as previously described by Gibson et al. (2015) .
Hypoxic exposures
Upon arrival, participants weighed themselves and provided a urine sample. Urine-specific gravity (Uspg) was assessed using a refractometer (Atago Co., Tokyo, Japan), and urine osmolality (Uosm) was measured using an osmometer (Pocket PAL-OSMO; Vitech Scientific, Horsham, UK). Euhydration was achieved when Uosm and Uspg were below 700 mOsmol/ kg H 2 O and 1.020, respectively (Sawka et al., 2007) . Participants were required to consume 500 mL of water and wait 30 min before they entered the chamber if they were above the criteria (MacKenzie et al., 2008) . Participants then sat and rested for 15 min for a resting heart rate (HR) and O 2 saturation (SpO 2 ) to be measured prior to entering the chamber. Following this period, participants spent 2 h resting in a normobaric hypoxic chamber achieved using a purpose-built, Values are mean AE SD.
[EPO], erythropoietin concentration; IL-6, interleukin-6; TNFa, tumor necrosis factor alpha. remaining 6 h, participants rested in normoxic conditions in temperate laboratory conditions. FiO 2 was measured in the chamber every 15 min. SpO 2 was measured every 15 min, should a participant remain below 70% they were removed from the chamber (zero incidences). The Lake Louise Questionnaire was also completed every 30 min to assess for symptoms off AMS. Should a participant remain at 6 or above, they were removed from the chamber (zero incidences).
TESTING DAY

Exposure
Physiological measures
Heart rate (Polar 810i heart rate monitor; Kempele, Finland) and SpO 2 (Nonin 2500, Nonin Medical Inc., Plymouth, MN, US) were measured every 15 min while in the hypoxic chamber and every 30 min outside of the chamber. The measurement was recorded after 30 s.
Hematological measures
For venous blood sampling, a cannula (18G 9 1.5″ BD Venflon I.V. Cannula; BD Infusion Therapy AB, Helingborg, Sweden) was positioned in the anticubital fossa. Blood samples were taken before entering the chamber, after 1 and 2 h while in the chamber, and at 4, 6, and 8 h outside the chamber. After discarding the first 1 mL, venous blood was collected (~8 mL) with a plastic syringe (10 mL BD Plastipak; Becton & Dickinson UK, Oxford, UK) and dispensed into two 5-mL K-EDTA collection tubes (Sarstedt Ltd, Leicester, UK) prior to centrifugation at 2200 rpm (Eppendorf Refrigerated Centrifuge Model 5702R; Eppendorf UK Ltd, Stevenage, UK) for 15 min to separate plasma. Plasma was pipetted (Eppendorf Research/Research Pro) into 1.5 mL microtubes (Western Laboratory Service, Hampshire, UK) and stored at a À85°C (Sanyo Ultra Low, VIP Series, Watford, UK) until the samples were analyzed.
[EPO], IL-6, and TNFa concentrations were measured in plasma for all four trials (SL, 3600, 4200, and 4800 m). Enzyme-linked immunosorbent assays were used in accordance with manufacturer instructions to determine concentrations for [EPO] (Roche Diagnostics Ltd, Lewes, UK) and for IL-6 and TNFa (DuoSet ELISA Development System; R&D Systems Inc., Abingdon, UK). The technical error of measurement (TEM) between duplicate samples for [EPO] was 3.8%, with a unit error value of 0.7 mU/mL; for IL-6, it was 7.1%, with a unit error value of 2.76 pg/mL; and for TNFa, it was 4.1%, with a unit error value of 518.7 pg/mL.
Statistical analysis
Data were assessed for normality and sphericity and adjusted where necessary using the Huynh-Feldt method. Differences in [EPO], IL-6, and TNFa at each time point (e.g., before, 1, 2, 4, 6, and 8 h), HR and SpO 2 were analyzed with a two-way repeated-measures ANOVA (hypoxia 9 time), with Bonferroni correction used to determine differences between conditions. For statistical analysis, SpO 2 and HR measurements were averaged for each hour in the chamber and every 2 h outside of the chamber. A Pearson product-moment correlation was used to characterize the association between peak D[EPO] and desaturation during hypoxic exposure, baseline IL-6, and baseline TNFa. TEM calculations were carried out on duplicate [EPO], IL-6, and TNFa samples using a method previously described by Hopkins (2000) . All statistical tests were completed using SPSS Statistics 22 (International Business Machines Corp., Armonk, New York, USA). Significance was accepted at P < 0.05. Values are reported as mean AE SD unless otherwise indicated. Effect sizes for main effects and interactions are presented as partial eta squared (g p 2 ) in accordance with Lakens (2013) .
Results
Physiological measures
There was an effect on SpO 2 over time (F = 927.298, P = 0.001, g p 2 = 0.99), in hypoxia (F = 258.717, P = 0.001, g p 2 = 0.97), and an interaction effect between time 9 hypoxia (F = 156.411, P = 0.001, g p 2 = 0.96). Bonferroni comparison identified significant differences between pre-exposure (Pre) and during exposure (1 h/2 h), respectively, at 3600 m (P = 0.001), 4200 m (P = 0.001), and 4800 m (P = 0.001). Between trials, significant differences in SpO 2 were found at 1 h (P = 0.001) and 2 h (P = 0.001) between SL (98 AE 0 and 98 AE 1%), 3600 m (87 AE 2 and 87 AE 3%), 4200 m (83 AE 1 and 83 AE 1%), and 4800 m (76 AE 2 and 75 AE 3%). No differences were found within the SL trial. Post-hoc data are presented in Fig. 3(a) .
There was an effect on HR over time (F = 21.294, P = 0.001, g p 2 = 0.75), in hypoxia (F = 11.739, P = 0.001, g p 2 = 0.63), and an interaction effect between time 9 hypoxia (F = 9.837, P = 0.001, g p 2 = 0.59). Bonferroni comparison identified significant differences (P = 0.022) between mean HR at SL (57 AE 7 beats/min) and 4800 (65 AE 10 beats/ min). At SL, no differences were observed over time. At 4200 and 4800 m, HR was significantly higher (P < 0.05) at 1 h (66 AE 5 and 75 AE 8 beats/min) and 2 h (63 AE 6 and 72 AE 10 beats/min), respectively, compared with 4 h (58 AE 4 and 61 AE 9 beats/ min), 6 h (58 AE 6 and 60 AE 7 beats/min), and 8 h (55 AE 8 and 58 AE 9 beats/min). Post-hoc data are presented in Fig. 3(b) .
Hematological measures
An effect on [EPO] was observed over time (F = 9.959, P = 0.001, g p 2 = 0.59). Mean [EPO] peaked at 4 h in 3600, 4200, and 4800 m. No differences were observed in [EPO] from pre-exposure (5.36 AE 1.61 mU/mL) to 8 h (6.4 AE 1.45 mU/mL) during the SL trial. Bonferroni comparison identified a difference in [EPO] between Pre and 4 h at 4200 m (P = 0.009) and at 4800 m (P = 0.037), but not at 3600 m. There was no main effect for hypoxia (F = 0.359, P = 0.704, g p 2 = 0.05) nor an interaction effect between time 9 hypoxia (F = 1.296, P = 0.250, g p 2 = 0.16). Figure 4 illustrates the response of plasma [EPO] during each trial.
No effect on IL-6 was found over time (F = 0.683 P = 0.547, g p 2 = 0.09), simulated hypoxia (F = 0.242, P = 0.789, g p 2 = 0.03), or an interaction effect between time 9 hypoxia (F = 0.465, P = 0.907, g p 2 = 0.06). Figure 5 illustrates the response of plasma IL-6 during each trial.
There was also no effect on TNFa found over time (F = 1.748, P = 0.1.82, g p 2 = 0.20), hypoxia (F = 0.945, P = 0.412, g p 2 = 0.12), or an interaction effect between time 9 hypoxia (F = 1.545, P = 0.142, g p 2 = 0.18). Figure 6 illustrates the response of plasma TNFa during each trial.
Relationship between peak [EPO] and other measures
No correlation (P > 0.05) was found between desaturation during hypoxic exposure and peak D[EPO] (r = À0.106) across all three hypoxic trials (Fig. 7a) . Further to this, no correlation (P > 0.05) was found between peak D[EPO] and baseline IL-6 (r = 0.140) (Fig. 7b) and also between peak D[EPO] and baseline TNFa (r = 0.159) (Fig. 7c) .
Discussion
The novel findings of this study were that a normobaric hypoxic exposure of 2 h at an FiO 2 of <0.125 . Difference in arterial oxyhemoglobin saturation (SpO 2 ; a) and heart rate (HR; b) after 2 h exposure to SL, 3600, 4200, and 4800 m. Values are mean AE SD. ( † P ≤ 0.05 denotes differences from Pre, ‡ P ≤ 0.05 denotes differences from 1 h, and *P ≤ 0.05 denotes differences from 2 h). The gray box illustrates the exposure time. Note 3600 and 4200 m error bars removed for clarity. (>4200 m) are sufficient to increase EPO production, which peaked 2 h post-exposure and are maintained up to 4 h post-exposure. Despite observing a greater increase in [EPO] as a result of increased severity of hypoxia, large individual variability (Table 2) between participants resulted in no main effect from hypoxia itself. All [EPO] returned to baseline levels 6 h post-exposure. This study also found that there was no relationship between baseline IL-6 and TNFa and peak D [EPO] . There were also no differences in IL-6 and TNFa production as a result of three different hypoxic severities. Values are mean AE SD.
EPO response to normobaric hypoxia
[EPO], erythropoietin concentration; IL-6, interleukin-6; TNFa, tumor necrosis factor alpha. at~5500 m elicited a~50% increase in [EPO], and Ge et al. (2002) also found an increase of~50% in [EPO] after 24 h of hypobaric hypoxia at~2500-2800 m. For the application of a hypoxic exposure on return to sea level post-altitude training camp, normobaric hypoxia is the most accessible option, at a moderate to high altitude (<4000 m), and at a short enough duration that it would fit into an athletes' daily training schedule (<2 h). Chronically increased EPO synthesis leads to a progressive increase in tHbmass (Lundby et al., 2007) ; however, hypoxia-induced changes in EPO release seem to be subject to a marked inter-individual variability (Chapman et al., 1998) . This may explain why there is a varied athlete response in tHbmass to altitude training camps (Mclean et al., 2013) . In our study, despite a greater reduction in SpO 2 from an increased severity of hypoxia causing a greater production in [EPO] , individuals who were more O 2 desaturated did not always produce a greater [EPO] (Fig. 7) . As such, the findings are in agreement with previous literature (Ge et al., 2002; Friedmann et al., 2005; MacKenzie et al., 2008) , who also found a marked individual variability in EPO release at different altitudes. Although the participants in this study were well trained, similar values and variations of [EPO] have been reported in elite athletes (Clark et al., 2009; Garvican et al., 2012; Pottgiesser et al., 2012) .
The exact mechanisms for individual variability in EPO response to altitude are not well determined (Fudge et al., 2012) . Chapman et al. (2010) found that there was no correlation between changes in EPO at altitude and hypoxic ventilatory response measured at sea level, suggesting that peripheral chemoresponsiveness may not be responsible for the variability in EPO response, and the likely mechanisms may be downstream from the lung. Ge et al. (2002) , however, believed EPO production at altitude is governed by "upstream" factors related to renal parenchymal PO 2 , as well as other undetermined mechanisms, possibly related to transcriptional regulation of EPO by renal tissue hypoxia. Alternatively, proinflammatory cytokines have been shown to trigger the suppression of renal EPO production and therefore erythropoiesis (Morceau et al., 2009) , with the inhibition of EPO production shown in vitro and in vivo to potentially involve IL-1, IL-6, and TNFa (Morceau et al., 2009 ). However, this study found that baseline IL-6 and TNFa did not correlate with the peak D[EPO], and there were no differences in IL-6 and TNFa production as a result of three different levels of hypoxia.
The present investigation found no relationship between DSpO 2 and peak D[EPO] percentage. MacKenzie et al. (2008) suggested EPO production is noticeably augmented by the depression of arterial O 2 content (CaO 2 ), as a result of decreases in SpO 2 . Therefore, a greater reduction in SpO 2 combined with an inability to increase HVR could facilitate a greater secretion of EPO (Jelkmann, 1992) . Ge et al. (2002) also suggested that the mechanism of an individual response to altitude is likely to include the greater oxyhemoglobin desaturation. This occurs as the PO 2 falls to the steep portion of the oxyhemoglobin dissociation curve, and therefore, changes in SpO 2 are mirrored by EPO levels at all altitudes. The investigations by Ge et al. (2002) and MacKenzie et al. (2008) only found a moderate relationship between DCaO 2 /DSpO 2 and changes in EPO.
Inflammatory response to normobaric hypoxia
Hypoxia and inflammation are interrelated at molecular, cellular, and clinical levels (Eltzschig & Carmeliet, 2011) . Oxidative stress and the release of proinflammatory cytokines (e.g., IL-1, IL-6, TNFa), which are systemic inflammatory markers, are closely associated with acute hypoxia and are proportional to the severity of hypoxia (He et al., 2014) . Previously, Klausen et al. (1997) found that after 1 day at 4350 m, there was a non-significant change in serum IL-6 by 56% and by day 4 had significantly increased by 86%; however, there were no changes in IL-1 or TNFa. The increase in IL-6 was significantly correlated (r = À0.45) with hypoxemia (mean SpO 2 : 79-83%), but not HR or symptoms of AMS. The authors suggested that the increase in serum IL-6 was not secondary to increased sympathetic nervous activity or general distress during altitude acclimatization due to the lack of relation between serum IL-6 and heart rates or AMS scores.
This investigation found that baseline levels of IL-6 and TNFa are not associated with the production of EPO (Fig. 7b/c) . Furthermore, there were no difference in IL-6 and TNFa at three levels of normobaric hypoxia, despite increases in HR and decreases in SpO 2 . Jelkmann et al. (1992) found that the addition of IL-1 and TNFa inhibited the production of EPO in hypoxic human hepatoma cell cultures; however, inhibition did not occur with introduction of IL-6, thus believing that IL-1 and TNFa have been shown to affect gene expression in human hepatoma cultures at the transcriptional level (Jelkmann et al., 1994) . The authors reported that IL-6 does not affect EPO production in vitro; moreover, IL-6 appears to inhibit renal EPO formation. Inflammatory responses to hypoxia are complex with various cytokines both inhibiting and preserving the production of EPO. At present, it is not clear what proinflammatory cytokines regulate the production of EPO, but in this investigation, inflammation did compromise endogenous [EPO] .
Future directions
Additional normobaric hypoxic exposures of 2 h, with the aim of increasing the production of EPO, have not been implemented on return to sea level after an altitude training camp. Rodr ıguez et al. (2000) and Casas et al. (2000) exposed trained volunteers to hypobaric hypoxia at simulated altitudes of 4000-5000 m for 90 min, three times a week for 3 weeks. This stimulus led to an effective stimulation of erythropoietic adaptations, such as significant increases in red blood cell (RBC) count, [Hb] , and reticulocytes. Katayama et al. (2003) , however, utilized a similar protocol (4500 m for 2 h, three times a week for 3 weeks) with endurance runners and found no changes in hematological parameters, including [Hb] , Hct, RBC count, reticulocytes, or EPO. The large individual variation and differing populations used could account for these contradictory findings; nevertheless, the protocol should be tested post-altitude training camp alongside measurement of EPO and tHbmass.
Further to this, tighter controls surrounding exhaustive exercise pre-hypoxic exposure should be considered, as different types of exercise (concentric, eccentric, submaximal, and maximal) are known to cause increases in proinflammatory cytokines (Pedersen et al., 1998; Nieman et al., 2001; J€ urim€ ae et al., 2011) , and intense exercise provides a physiological stimulus to increase EPO production (Roberts & Smith, 1999) . Additional modifications to the protocol could include blood samples 12, 14, and 48 h post-hypoxic exposure to determine if there is a delayed increased in EPO or proinflammatory cytokines as has previously been suggested (Pedersen et al., 1998; Ge et al., 2002) . This investigation did control for diurnal variations in hematological markers by ensuring that all trials were started between 07:30 and 09:30 hours, as previous research has shown that EPO is subject to distinct diurnal variation in trained and untrained individuals (Klausen et al., 1993) , as well as in both normoxia and hypoxia (Klausen et al., 1996) . Keramidas et al. (2011) observed diurnal variation of a nadir in values of EPO in the morning hours and zenith levels during the evening and night hours. Additional hematological measurements prior to the experimental period would provide a more accurate baseline interpretation.
Practical applications
A decrease in EPO and tHbmass on return to sea level has been observed in athletes after altitude training camps lasting 3-4 weeks (Heinicke et al., 2005; Clark et al., 2009; Garvican et al., 2012; Pottgiesser et al., 2012) . When red cell mass exceeds the physiological requirement at the altitude resided in, EPO secretion is suppressed (Rice & Alfrey, 2005) and a destruction in red cells, or neocytolysis, occurs. Athletes who are acclimated after an altitude training camp and who then descend to sea level to compete would have red cell mass that is higher than necessary for homeostasis to their new environment. The rapid destruction of reticulocytes and the decline in production of new ones may depend on a drop in EPO levels (Alfrey et al., 1997) . Additionally, EPO not only regulates red cell mass but also prolongs its survival (Rice et al., 2001) . For an athlete with a faster than normal decline in tHbmass upon return to sea level competing as soon as possible may be the most beneficial strategy, but this is not always logistically achievable. Additional hypoxic exposures have been suggested as strategy to prevent the sudden drop off in EPO (Pottgiesser et al., 2012 ).
An athlete's busy travel schedule, external commitments, and competition program make it difficult to time competing at sea level after an altitude training camp. Chapman et al. (2014) , suggested that if an athlete completes a 4-week altitude training camp, followed by a short time (~7-14 days) at sea level to compete, returning to altitude even for a short time may mitigate or delay the effects of neocytolysis by re-establishing EPO levels, although this has not been proven. This is not for added erythropoiesis, as is typically done with altitude residence, but more to delay the selective destruction of reticulocytes due to lower than baseline EPO concentrations, as a result of the athlete just remaining at sea level. By keeping EPO elevated, in addition to preventing neocytolysis, exercise performance might be improved (Schuler et al., 2012; Durussel et al., 2013) .
Perspectives
In Caucasian populations, erythropoiesis is a key acclimatization response that increases the O 2 -carrying capacity of the blood, i.e., tHbmass, as a result of chronic exposure to altitude (Chapman et al., 2013) . A change in tHbmass by 1 g causes a change in V O 2max by approximately 4 mL/min , for an athlete increased blood gas storage capacity is very important; therefore, the maintenance of tHbmass should be considered. Chapman et al. (2014) stated that brief, short-term periods of normobaric hypoxia may provide a sufficient stimulus to significantly increase EPO, despite this not being enough to accelerate erythropoiesis itself. These exposures could take place during the day, around the athlete's training schedule, to preserve the hematologic acclimatization response for a longer time, thereby expanding the window for optimal competition. The increases in [EPO] found in the current investigation indicate that a normobaric hypoxic "dose" (i.e., FiO 2~0 .125-0.115, equivalent to 4200 m and above, for 2 h) may prevent the sudden drop in EPO that has been shown post-altitude and, therefore, maintain any enhancements in tHbmass. The release of EPO is subject to a distinct inter-individual variation that can only be partially explained by reductions in oxyhemoglobin saturation, but is not affected by systemic markers of inflammation.
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